Utidelone has the ability to cross BBB due to its unique physicochemical characteristic and insusceptibility to P-glycoprotein-mediated efflux
This turn valve is considered revolutionary because it supports back-to-back drug infusion through the same device
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
With this, the company has secured 511 marketing approvals for its oncology products across 66 countries
Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
The company has secured 506 marketing approvals for its oncology products across 76 countries.
CMOs showed an increasing reluctance to take on debt in 2022
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The company is already marketing the 4 mg and 10 mg strengths
This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable
Subscribe To Our Newsletter & Stay Updated
